October, 28 – 31, 2024 | Boston, MA www.proteindegradation.com

7th Annual

TPD & Induced Proximity Summit

Fast-Track Discovery, Development & Approval of Selective, Safe & Clinically Relevant TACs & Glues for Degradation, Stabilization, & Phosphorylation to Successfully Address Unmet Need in Oncology & Beyond

450+ TPD Expert Attendees

85+ World-Class Expert Speakers

4 Days of Unparalleled New Data

3 Tracks Of Parallel Talks For You & Your Team

85+ World-Class Speakers, Including:

Alessio Ciulli
Director of the Centre for Targeted Protein Degradation
University of Dundee

Stuart Schreiber
Morris Loeb Professor, Emeritus Howard Hughes Medical Institute Investigator
Harvard University

Christina Woo
Morris Kahn Associate Professor
Harvard University

Eric S. Fischer
Professor
Harvard Medical School
Director
DFCI Center for Protein Degradation

Nello Mainolfi
Founder, President & Chief Executive Officer
Kymera Therapeutics

Adrian Gottschalk
Chief Executive Officer
Foghorn Therapeutics

John Houston
Chairperson, President & Chief Executive Officer
Arvinas

Arthur Sands
Chief Executive Officer
Nurix Therapeutics

Andrew Hirsch
President & Chief Executive Officer
C4 Therapeutics

Filip Janku
Chief Medical Officer
Monte Rosa Therapeutics

Neil Bence
Vice President, Oncology Discovery
Bristol Myers Squibb

Chinatsu Sakata-Sakurai
Vice President
Astellas

Greg Michaud
Director
Novartis

Johan Johansson
Associate Principal Scientist PROTAC Lead
AstraZeneca

Arnout Schepers
Founder & Chief Executive Officer
TenAces Bio

Maureen Spit
Vice President
Laigo Bio

Promega

+1 617 455 4188 | info@hansonwade.com | @Undruggable | Targeted Protein Degradation | www.proteindegradation.com

hansonwade

CONTENTS

REGISTER NOW

Welcome to the **7th TPD & Induced Proximity Summit**

With a flurry of high capital collaborations and partnership deals from the likes of **C4**, **Merck, Monte Rosa**, **Proxygen**, **Orum**, and momentum building in clinic with BTK degraders, ER degraders and many more assets, TPD and induced proximity therapeutics have never looked more poised for success from both a discovery and clinical perspective.

It's this excitement that is driving the community to re-join forces at the **7th TPD & Induced Proximity Summit**, the **longest-standing and most comprehensive protein degradation and proximity-based conference**, returning to Downtown Boston, packed with new data and world leading speakers to guide your TPD and induced proximity strategies and pipelines towards patients in need. This summit will spotlight the opportunities and challenges that the field must address to expand the target space and facilitate the discovery and development of therapeutically relevant degraders, stabilizers and protein modulators as frontier medicines of the future.

The Most Premier One-Stop-Shop For You & Your Team to:

- Cut through the noise and access genuinely innovative, field-changing research unearthing novel targets & pathways in Oncology, CNS, Cardiology & beyond
- Harness new tools and techniques when applying structure-based drug design in degrader discovery to more accurately make binding predictions
- Leave serendipity behind to discover and develop molecular glues rationally by design and expand the glue paradigm with greater ligase & neosubstrate affinity
- Optimize bi-functionals efficiently to effectively create potent, soluble, permeable, and lower molecular weight compounds to garner smooth translation from animal studies to clinical trials
- Encourage greater safety through selective degrader development, toxicology data, and robust safety assessment protocols to cement degrader's value proposition as an outstanding therapeutic intervention

Designed with the needs of a Senior Scientist, a C-level Executive, and a total newcomer at the front of mind, the **7th TPD & Induced Proximity Summit** is here to help you access vital information and connections to achieve good ligandability, oral bioavailability, PKPD and clinical efficacy, to deliver your degrader/modulator towards approvals and to patients faster.

4 Sessions You Cannot Miss:

7th Annual TPD & Induced Proximity Summit

October 28 - 31 | Boston, MA

CEO Think Tank:

Define your degrader pipeline & asset strategy going forward to limit setbacks by acquiring first-hand insight from the CEO's of **Kymera**, **Arvinas**, **Nurix**, & **Foghorn**

AI/ML, All Smoke No Fire?

Amid speculation surround AI/ML utility, cut through the noise with data-driven talks from **Deargen**, **Monte Rosa**, & **TenAces** harnessing these tools to enable rational molecular glue discovery & design

Translating DMPK

You spoke, we listened. This year we have more DMPK & PK/PD modeling talks than ever before. Equip your chemists with the insights needed to rapidly optimize your molecule & progress from preclinic to patients fast with **Stew Fisher**, CSO, **C4 Therapeutics** & **Brad Heckmann**, CSO, **Asha**.

600+ E3 Ligases

We have barely scratched the surface with the E3 Ligase family. Maybe more important is finding their Ligands. Bolster your own approach to identifying these with talks from **Amgen**, **Cullgen**, & **A-Alpha Bio.**

> "The TPD Summit improves each year, with more presenters willing to share structures & data"
>
> **Research Emerging Therapeutic & Platforms Fellow, AbbVie**

CONTENTS

REGISTER NOW

What's New for 2024?

7th Annual TPD & Induced Proximity Summit
October 28 - 31 | Boston, MA

New Frontiers in TPD & Induced Proximity Research Day

Presenting their latest work on molecular glues and intramolecular bivalent glues, these legends of the TPD field will take to the stage on the very first day of the summit (October 28) within our brand new, ***New Frontiers in TPD & Induced Proximity Research Day***, featuring exclusively Key Opinion Leading academics

Alessio Ciulli
Founder, Director & Professor
University of Dundee

Stuart Schreiber
Founding Chief Executive Officer
Arena Bioworks

CEO Think Tank

Kicking off our first industry-focused day (October 29), the Chief Executive Officers from the field's leading biotechs will share their personal thoughts on the current state-of-play, in a series of carefully curated sessions designed to glean precious insights from the minds of the foremost thinkers in the field of protein degradation!

Nello Mainolfi
Chief Executive Officer
Kymera Therapeutics

Andrew Hirsch
President & Chief Executive Officer
C4 Therapeutics

John Houston
Chief Executive Officer
Arvinas

Arthur Sands
Chief Executive Officer
Nurix Therapeutics

Adrian Gottschalk
Chief Executive Officer
Foghorn Therapeutics

Neil Torbett
Chief Executive Officer
Phoremost

New Clinical Progress

On October 30 we welcome to our **Keynote**, **Plenary** session, **Nurix Therapeutics** presenting clinical updates on degraders in clinic! You will not want to miss this!

Accelerating Partnerships & Investments in TPD

The field of dealmaking and collaboration in TPD has shown no signs of slowing over the past 6 months, with **Merck US & KgGA**, **C4 Therapeutics**, **Novo Nordisk**, **Monte Rosa**, **Nurix**, **Seagen**, **Neomorph**, **Bristol Myers Squibb**, **Orum**, **Novartis** and so many more striking multi million $ deals to secure future development of degraders in 2025 and beyond.

This is why we're introducing for the first time, a dedicated session exploring **trends in platform and assets deals across the TPD space** uniting the very people involved in those deals

Jason Kantor
Chief Business Officer
Nurix Therapeutics

Barbara Lueckel
Global Head, Research Technologies Partnering Pharma Partnering
F. Hoffmann-La Roche

Randy Teel
Chief Business Officer
Arvinas

Scott Boyle
Chief Business Officer
C4 Therapeutics

CONTENTS

REGISTER NOW

JOIN US AS WE COVER THE LENGTH, BREADTH & DEPTH OF THE TPD & INDUCED PROXIMITY LANDSCAPE

October 28 - 31 | Boston, MA

7th Annual TPD & Induced Proximity Summit

CONTENTS

REGISTER NOW

Your Expert Speakers | World-Leading Academics

7th Annual TPD & Induced Proximity Summit

October 28 - 31 | Boston, MA

Alessio Ciulli
Founder, Director & Professor
University of Dundee

Stuart Schreiber
Founding Chief Executive Officer
Arena Bioworks

Zoran Rankovic
Director, Centre for Protein Degradation
The Institute for Cancer Research

Eric S. Fischer
Professor
Harvard Medical School
Director
DFCI Center for Protein Degradation

Jian Jin
Professor & Director
Icahn School of Medicine at Mount Sinai

Stephanie Leuenroth-Quinn
Pharmacologist
US Food & Drug Administration (FDA)

Christina Woo
Assistant Professor
Harvard Medical School

Andrew Tsourkas
Professor
University of Pennsylvania



Christian Ottmann
Associate Professor
Eindhoven University of Technology



Daniel Finley
Professor
Harvard Medical School

Elena De Vita
Worldwide Cancer Research Co-Investigator
Imperial College London

Gary Kleiger
Chair & Professor
University of Nevada School of Medicine

Gisele Nishiguchi
Group Leader
St. Jude Children's Research Hospital



Kylie Walters
Senior Investigator
Structural Biophysics Laboratory
National Institutes of Health



Radoslav Enchev
Group Leader
The Francis Crick Institute



Dmitri Ivanov
Associate Professor
UT Health San Antonio



Raegan O'Lone
Senior Program Advisor
HESI



Jarrod Marto
Principal Investigator
Dana-Farber Cancer Institute

CONTENTS

REGISTER NOW

Your Expert Speakers | Global Pharma & Biotech Leaders

7th Annual TPD & Induced Proximity Summit

October 28 - 31 | Boston, MA

John Houston
President & Chief Executive Officer
Arvinas



Nello Mainolfi
Founder, President & Chief Executive Officer
Kymera Therapeutics

Arthur Sands
Chief Executive Officer
Nurix Therapeutics

Adrian Gottschalk
Chief Executive Officer
Foghorn Therapeutics

Andrew Hirsch
President & Chief Executive Officer
C4 Therapeutics

Neil Torbett
Chief Executive Officer
Phoremost

Len Reyno
Chief Medical Officer
C4 Therapeutics

Filip Janku
Chief Medical Officer
Monte Rosa Therapeutics



Steven Bellon
Chief Scientific Officer
Foghorn Therapeutics



Stewart Fisher
Chief Scientific Officer
C4 Therapeutics

Greg Michaud
Director
Novartis AG

Paula O'Connor
Chief Medical Officer
Nurix Therapeutics

Neil Bence
Vice President, Oncology Discovery
Bristol Myers Squibb



Eugene Chekler
Director & Head of Chemistry
Bristol Myers Squibb

Jason Kantor
Chief Business Officer
Nurix Therapeutics

Juliet Williams
Head of Research
Kymera Therapeutics



Harris Bell-Temin
Director - Proteomics
Johnson & Johnson Innovative Medicine

Randy Teel
Chief Business Officer
Arvinas



Scott Boyle
Chief Business Officer
C4 Therapeutics

Barbara Lueckel
Global Head, Research Technologies Partnering, Pharma Partnering
F. Hoffmann-La Roche

Bernd Boidol
Chief Executive Officer
Proxygen



Abhishek Dogra
Director Medicinal Chemistry & Induced Proximity
A-Alpha Bio

Amine Sadok
Director, Induced Proximity Platform
Amgen

Andreas Reichel
Vice President, Head Of DMPK Modelling & Simulations
Bayer

CONTENTS

REGISTER NOW

Your Expert Speakers | Global Pharma & Biotech Leaders

7th Annual TPD & Induced Proximity Summit

October 28 - 31 | Boston, MA

Ankit Sharma
Associate Director, Medicinal Chemistry, Oncology Targeted Discovery
AstraZeneca

Zhifeng Yu
Director of Assay & DEL Screening
WuXi Apptec

Karteek Kadimisetty
Director R&D
LifeSensors



Arnout Schepers
Founder & Chief Executive Officer
TenAces Biosciences

Arvind Shakya
Director
BioTheryx



Benedict Cross
Chief Technology Officer & Head of Platform
PhoreMost

Bradlee Heckmann
Co-Founder & Chief Scientific Officer
ASHA therapeutics

Carolyn Porter
Chief Executive Officer
Outrun Therapeutics

Chinatsu Sakata-Sakurai
Vice President
Astellas Pharma



Christian Dillon
Chief Scientific Officer
PhoreMost

Charu Chaudhry
Associate Director
Johnson & Johnson Innovative Medicine

Diogo Felciano
Co-Founder & Chief Scientific Officer
Booster Therapeutics

Effie Tozzo
Chief Scientific Officer
Avilar Therapeutics

Gang Yao
Associate Director Encoded Technologies
GlaxoSmithKline



Giovanni Spagnolli
Co-Founder & Chief Technology Officer
Sibylla Biotech

Hailong Zhang
Chief Executive Officer
Blueray Biopharma

Jaehyun Choi
Chief Executive Officer
EPD Biotherapeutics

JF Brazeau
Director
Plexium



Joachim Rudolph
Senior Fellow Discovery Chemistry
Genentech

Johan Johansson
Associate Principal Scientist PROTAC Lead
AstraZeneca

Vivek Vishnudas
Chief Technology Officer & R&D Site Head
BPGBio



Kanak Raina
Senior Director
Halda Therapeutics

Ken Yamada
Associate Director
Novartis AG

Keunsoo Kang
Chief Scientific Officer
Deargen

CONTENTS

REGISTER NOW

Your Expert Speakers | Global Pharma & Biotech Leaders

7th Annual TPD & Induced Proximity Summit

October 28 - 31 | Boston, MA

Leo Fu
Co-Founder & Chief Technology Officer
GluBio Therapeutics

Lise Loberg
Preclinical Safety Expert
AbbVie

Nina Ilic-Widlund
Director - Oncology
Monte Rosa Therapeutics

Matthias Brand
Co-Founder & Chief Scientific Officer
Proxygen



Mark Niosi
Principal Scientist
Pfizer



Michael Chen
Chief Executive Officer
Nuclera

Maureen Spit
Vice President Research
Laigo Bio

Nan Ji
Co-Founder, President & Chief Executive Officer
PAQ Therapeutics

Natalie Nairn
Chief Executive Officer
Cyclera Therapeutics

Pat Sharp
Co-Founder & Vice President Discovery Sciences
Gate Bioscience

Peggy Scherle
Chief Scientific Officer
Prelude Therapeutics



Randolph Lopez
Co-Founder & Chief Technology Officer
A-Alpha Bio

Riccardo Sabatini
Chief Data Scientist
Orionis Biosciences



Atul Tiwari
Vice President - Discovery Strategy
Sai Life Sciences

Katie Spooner
Research Analyst
Beacon

Rick Ewing
Vice President & Head of Chemistry
Rapafusyn Pharmaceuticals



Anita Bellail
President & Chief Executive Officer
HB Therapeutics

Ryan Kerrigan
Principal Scientist II
Novartis AG

William Housley
Principal Scientist Research
AbbVie



Wu Du
Senior Vice President
Hinova Pharmaceuticals

Xiaoran Han
Vice President Discovery Medicine
Cullgen

Yao Wang
Chief Medical Officer
Kangpu Biopharmaceuticals

Ya-Wen Lu
Associate Director
Nurix Therapeutics

Sean Zhu
Senior Director - Computational Chemistry
Kymera Therapeutics

CONTENTS

REGISTER NOW

Your Expert Speakers | Global Pharma & Biotech Leaders

7th Annual TPD & Induced Proximity Summit

October 28 - 31 | Boston, MA

Yong Cang
Co-Founder & Chief Scientific Officer
Degron Therapeutics

Ethan Toriki
Discovery Postdoctoral Fellow
Novartis



Jessica Sims
Principal Scientist Toxicology
Genentech

Elizabeth Caine
Senior Scientist
Promega



Ian Churcher
Consultant
Janus Drug Discovery

Henrik Daub
Founder & Chief Scientific Officer
NEOsphere Biotechnologies



Sarah Carratt
Principal Scientist
Pfizer



Andrew Potterton
Head of Platform
Ternary Therapeutics

Ryan Cross
Senior Science Correspondent
Endpoints News

Chris Heger
Director - Applications Science
Bio-Techne

Kelly Rainbolt
Senior Scientist
Lyterian Therapeutics

Shyra Gardai
Chief Scientific Officer
EpiBiologics



John (JP) Guilinger
Senior Director, Lead Discovery & Biochemistry
X-Chem

"Great talks, diverse set of sessions, the TPD & Induced Proximity Summit has all the key TPD players in one place!"

Associate Director, Relay Therapeutics

CONTENTS

REGISTER NOW

Agenda at a Glance

7th Annual TPD & Induced Proximity Summit

October 28 - 31 | Boston, MA

limited spaces remaining

New Frontiers & Mechanistic Day
Monday October 28

Check In & Coffee

Workshop Day	TPD Assay Development & Screening Day NEW	TPD 101 Bootcamp Day NEW	New Frontiers in TPD & Induced Proximity Day
Integrating Structural Dynamics Studies into Drug Discovery	Discovery Assay Development	Introducing the Fundamentals of TPD	Molecular Glues, Cereblon Studies, & Novel Technologies

Networking Lunch Break

Optimizing Physicochemical & ADME Properties	Tailored Assay & Screening Design to Create New Avenues for Your Candidate	Meet the E3 Ligase Family	Unearthing Novel Degrader Findings to Accelerate Discovery with Structural Biology Data

Afternoon Break & Networking

Computational Approaches & AI/ML Tools of Targeted Protein Degradation	New Ligase & New Ligand Understanding with Novel *In Vitro* & *In Vivo* Assay Design	Full Potential of Protein Degradation Machinery with New Applications	Discovery & Understanding of Novel PROTACs & New Degraders

End of New Frontiers & Mechanistic Day

Industry Day One
Tuesday October 29

Check In & Coffee

The Future of TPD & Beyond: The CEO Perspective NEW

Morning Break & Networking

Track A: Discovery	Track B: Preclinical	Track C: Clinical
Rational Discovery & Design of Molecular Glues	DMPK & Safety of Preclinical PROTACs	Safety Profiles & Toxicology of PROTACs in Clinic

Networking Lunch Break

Advanced Platforms for Discovering Novel E3 Ligands & E3 Ligases Rapidly	DMPK & Safety of Preclinical Molecular Glues	Efficacy Data from the Clinic to Inform Translation

Afternoon Break & Poster Session

Continued Novel E3 Ligands & E3 Ligases Rapidly	Continued DMPK & Safety of Preclinical Molecular Glues	Continued Efficacy Data from the Clinic to Inform Translation

Annual TPD Awards

End of Industry Day One

Industry Day Two
Wednesday October 30

Check In & Coffee

Breakthrough First Disclosures Changing the Course of TPD Drug Development NEW

Morning Break & Networking

Track A: Discovery	Track B: Preclinical	Track C: Clinical
Novel Target & Pathway Identification & Selection	Optimization of Compound Medicinal Chemistry	Translation of DMPK from *In Vitro* to *In Vivo* to Promote Clinical Success

Networking Lunch Break

Unraveling MOA & Optimizing Binding of Selective Degraders	Preclinical Modeling, IND-Filing, & Regulation	Formulation, Scale-Up, & Trial Design Optimization for Degraders

Afternoon Break & Networking

NEW

Strategy, Partnering & Investment for TPD & Beyond

End of Industry Day Two

limited spaces remaining

Next Generation Protein Modulation Day
Thursday October 31

Check In & Coffee

Innovating Techniques to Stabilize, Phosphorylate, & Degrade Protein & Non-Protein Targets NEW

Morning Break & Networking

New Approaches to Stabilization of Targets

Lunch

Alternative Takes on Monovalent Degraders

End of TPD & Induced Proximity Summit 2024

CONTENTS

REGISTER NOW

New Frontiers In TPD & Induced Proximity Research Day

Monday, October 28

7 World-Leading Academics

7 Bespoke Presentations

5 Hours of Expert-Led Content

1 Unmissable Day

LIMITED PASSES REMAINING

With this session, we will showcase some of the most significant recent advances in our fundamental understanding of ways to identify and develop the induced-proximity-based therapeutics of tomorrow. Attendees will have the chance to hear from leading academics in the induced-proximity field to gain first-class insight into where the field is heading.

"The TPD & Induced Proximity Summit is an excellent meeting"

Chief Scientific Officer, Cullgen

Keynote Speakers:

Alessio Ciulli, Director of the Centre for Targeted Protein Degradation, **University of Dundee**

With his team in the Ciulli laboratory, Ciulli's works aim to develop small molecules inducing targeted protein degradation and modulating protein-protein interactions. Ciulli and his colleagues were the **first to produce an X-ray crystal structure of a class of PROTAC** simultaneously bound to the target protein and the E3 ubiquitin ligase. Much of Ciulli's research also contributed to studies on the **VHL E3 ligase**, especially in targeting the E3 ligase with small molecules.

Stuart Schreiber, Founding Chief Executive Officer, **Arena Bioworks**

With too many breakthroughs to name, key advances include the discovery that small molecules can function as **"molecular glues"** that promote protein–protein interactions, the co-discovery of mTOR and its role in nutrient-response signaling, the discovery of histone deacetylases and the demonstration that chromatin marks regulate gene expression, the development and application of diversity-oriented synthesis to microbial therapeutics, and the discovery of vulnerabilities of cancer cells linked to genetic, lineage and cell-state features, including ferroptotic vulnerabilities.

CONTENTS

REGISTER NOW

New Frontiers in TPD & Induced Proximity Research Day

Monday, October 28 2024

7th Annual TPD & Induced Proximity Summit

October 28 - 31 | Boston, MA

	8.00	**Check-in & Morning Coffee**
 **Ian Churcher** Consultant **Janus Drug Discovery**	8.45	**Chair's Opening Remarks**

Advancing Induced Proximity & Molecular Glues to Propel Degrader Discovery

 **Stuart Schreiber** Founding Chief Executive Officer **Arena Bioworks**	9.00	**Molecular Glues & Bifunctional Compounds: Therapeutic Modalities Based on Induced Proximity** • Exploiting similarity of molecular glues and bifunctional compounds to hot spots, missense mutations, and posttranslational modifications (PTMs) • Coming full circle from natural product glues to simple synthetic compounds back to natural product-like glue compounds with high structural diversity • Methods to discover cooperative molecular glues and bifunctionals for biomedical targets of interest
 **Eric S. Fischer** Professor **Harvard Medical School** Director **DFCI Center for Protein Degradation**	9.30	**Combining Structure & Large-Scale Proteomics Studies to Accelerate Degrader Discovery** • Large-scale proteomics have been transformative for the accelerated discovery of degraders • Innovation in structural studies enable structure guided design principles • Combining structural and large scale profiling data enabled predictive models
 **Vivek Vishnudas** Chief Technology Officer & R&D Site Head **BPGBio**	10.00	**A Novel & Differentiated Approach to Targeted Protein Degradation - Leveraging the Ubiquitin Conjugating Enzyme (E2) Family** • Ubiquitin Conjugating Enzymes are challenging to modulate pharmacologically using small molecules due to lack of druggable pockets • Fragment Based Drug Design for the Modified (PTM) - E2 complex enabled discovery of first in class ligands • Through E2 ligand extension and molecular design, efficacious bi-functional degraders have been developed for multiple proteins of interest
 **Christian Ottmann** Associate Professor **Eindhoven University of Technology**	10.20	**Molecular Glues Targeting Parkinson's & Alzheimer's Disease-Relevant 14-3-3 PPIs** • 14-3-3 proteins modulate pathology-related activities of aSyn, Tau and LRRK2 • Molecular glues of these interactions might provide new avenues for therapeutic intervention • X-ray crystallography and biophysics enable identification of molecular glue chemistry
	10.50	**Morning Break & Networking**

Rationalising Degrader Design to Create Clear Approaches to Starting a Program

 **Jian Jin** Mount Sinai Endowed Professor **Icahn School of Medicine Mount Sinai**	11.30	**Novel Technologies to Target Undruggable Proteins** • Bridged PROTAC, a novel approach to target undruggable proteins • Harness the USP7 deubiquitinase for DUBTAC development using non-covalent inhibitors of USP7 • AceTAC, a novel technology and modality for inducing targeted protein acetylation
 **Christina Woo** Morris Kahn Associate Professor **Harvard University**	12.00	**Chemical Biology Studies of the Thalidomide-Binding Domain of Cereblon** • Investigation of ligands for the thalidomide-binding domain of cereblon • Update on chemistry of formation the C-terminal cyclic imide modification recognized by cereblon • Mechanisms of regulating the thalidomide-binding domain of cereblon

REGISTER NOW

New Frontiers in TPD & Induced Proximity Research Day
Monday, October 28 2024

7th Annual TPD & Induced Proximity Summit
October 28 - 31 | Boston, MA

12.30 **Lunch Break**

1.30 **Panel Discussion: Looking Ahead: The Next Generation of Induced-Proximity-Based Therapeutic Discovery**

- Where is TPD field going next?
- What are the biggest unsolved challenges and how might they be addressed?
- Which induced-proximity modalities have the most potential to match success of PROTACs?

Moderator:

Ian Churcher
Consultant
Janus Drug Discovery

Panelists:

Alessio Ciulli
Professor & Director of the Centre for Targeted Protein Degradation
University of Dundee

Eric S. Fischer
Professor
Harvard Medical School
Director
DFCI Center for Protein Degradation

2.30 **Afternoon Break & Networking**

Advancing the Discovery & Deepening New Insights into Induced Proximity Mechanisms

Alessio Ciulli
Professor & Director of the Centre for Targeted Protein Degradation
University of Dundee

3.00 **New Twists in Mechanisms & Rational Design of Protein Degraders**

- Protein degraders (PROTACs, molecular glues) recruit a target protein to a ubiquitin E3 ligase, leading to the ubiquitination and subsequent proteasomal degradation of the target protein
- Degraders work via formation of a ternary complex target: degrader: ligase. Pioneering structural and biophysical studies have revealed molecular insights of degrader mechanism of action, and ushered their rational drug design
- This talk will highlight new twists in mechanisms (e.g. intramolecular bivalent glues); new approaches to degrader design (e.g. ternary complex-templated dynamic combinatorial chemistry); and new enabling tools to speed-up research in the community (e.g. CRBN-Midi and BromoTag)

Kylie Walters
Senior Investigator & Section Chief
National Institutes of Health

3.30 **Discovery & Targeting of an hRpn13 Product by PROTACs & Degraders**

NEW DATA

- The structure of hRpn13 with a small molecule binder was used to generate an hRpn13 PROTAC
- An hRpn13 PROTAC discovered hRpn13Pru which is generated by proteasomes with cell-type dependency
- A class of hRpn13Pru degraders was developed for preclinical application

Ian Churcher
Consultant
Janus Drug Discovery

4.00 **Chair's Closing Remarks**

4.15 **End of New Frontiers in TPD & Induced Proximity Day**

REGISTER NOW

TPD Assay Development & Screening Day

LIMITED PASSES REMAINING

Monday, October 28

Having run two outstanding **Assay Development & Screening** meetings in San Diego over the last two years, we realised this niche has so much insight to offer the wider protein degradation community. As such, we have decided to consolidate this meeting into the **7th TPD & Induced Proximity Summit** this year.

Built with the scientist in mind, this day is sculpted to uncover **novel assay** development technologies, **new approaches** to assay design, and developments in **high throughput screening** from leading pharma and biotech in the space.

Key Agenda Highlights:

MicDrop - Phenotypic DEL Screen in Droplets for TPD

Ken Yamada, Associate Director, **Novartis**

Identify Novel E3 Ligases via Rapid Screening of DNA-encoded Libraries

Gang Yao, Associate Director Encoded Technologies, **GSK**

"Excellent content & diversity of speakers"
Senior Scientist, Blueprint Medicines

9.00 AM Session

- Discovering & characterizing latent E3 ligase protein-protein interactions against 150 therapeutic targets
- A novel protein degradation modality to address multiple diseases
- Identify novel E3 ligases via rapid screening of DNA-encoded libraries

12.30 PM Networking Lunch Break

1.30 PM Session

- Optimizing Proteolysis Targeting Chimeras (PROTACs) for Oral Drug Delivery
- Deep proteomics screening enables the discovery of novel molecular glue targets
- Discovery & optimization of first-in-class molecular glue degraders of the WIZ transcription factor for fetal hemoglobin induction to treat sickle cell disease

NOVARTIS · AstraZeneca · Bristol Myers Squibb · cullgen · A-ALPHA BIO

CONTENTS

REGISTER NOW

TPD Assay Development & Screening Focus Day
Monday, October 28 2024

7th Annual TPD & Induced Proximity Summit
October 28 - 31 | Boston, MA

8.00 Check-in & Morning Coffee

Nina Ilic-Widlund
Director - Oncology
Monte Rosa Therapeutics

8.45 **Chair's Opening Remarks**

Novel Assay Design & High Throughput Screening Approaches to Accelerate Degrader Discovery

Abhishek Dogra
Director Medicinal Chemistry & Induced Proximity
A-Alpha Bio

9.00 **Discovering & Characterizing Latent E3 Ligase Protein-Protein Interactions Against 150 Therapeutic Targets**

- Over 100 protein-protein interactions were identified between therapeutically relevant targets and a diverse set of ligases
- A subset of these interactions was further characterized using site-directed mutagenesis to define the interface and explore the ability to modulate the interaction
- These protein-protein interactions were used to prioritize small molecule discovery campaigns aimed at identifying molecular glues

Ken Yamada
Associate Director
Novartis

9.30 **MicDrop - Phenotypic DEL Screen in Droplets for TPD**

- Introduction to the concept of directed serendipity, a small-molecule equivalent of directed evolution enabled by DNA-encoded molecular glue library
- Overview of MicDrop, a phenotypic DEL platform enabled by droplet microfluidics and DNA-encoded one-bead one-compound library technology
- Walk-through of POI degradation screen data demonstrating the robustness of the platform with bead replicates and discovery of new glue degrader hits

NEW DATA

Eugene Chekler
Director
Bristol Myers Squibb

10.00 **Predicting & Optimizing the Selectivity Profiles of Novel CELMoD Compounds**

- Unlike achieving potency and selectivity for traditional small molecule inhibitors, reducing degradation of neosubstrate off-targets is complicated by the ternary nature of the complex formed between the POI, CRBN, and the CELMoD agent
- Herein we disclose an analysis of our glutarimide CELMoD library using a simple algorithm to identify the interpretable chemical features correlated with selectivity profiles and general cytotoxicity
- We also disclose simple multiparameter optimization (MPO) functions for each neosubstrate using two to three parameters to predict whether new molecules will likely have undesired off-target degradation activity

NEW DATA

10.30 Morning Break & Networking

REGISTER NOW

TPD Assay Development & Screening Focus Day
Monday, October 28 2024

John (JP) Guilinger
Senior Director, Lead Discovery & Biochemistry
X-Chem

11.00 Discovery of novel proximity-inducing compounds using DEL screening

- DNA-encoded chemical libraries (DECL) containing >100 billion compounds with a high diversity of chemical structures enable discovery of novel binders that induce protein – protein interactions (i.e. PROTACs and molecular glues)
- Informed DECL screening strategies and workflows significantly impact discovery of PROTAC and molecular glues compounds
- Multiple independent projects yielded confirmed PROTACs and molecular glues discovered from DECL screens highlighting the value of DECL screening for hit discovery in the TPD field.

Gisele Nishiguchi
Group Leader
St. Jude Children's Research Hospital

11.30 Deep Proteomics Screening Enables the Discovery of Novel Molecular Glue Targets

- High throughput proteomics screening of Cereblon-focused molecular glue library
- Identification of potent and selective molecular glue degrader for novel target
- Mechanistic profiling highlighting ubiquitinomics and mutational studies

Gang Yao
Associate Director Encoded Technologies
GSK

12.00 Discovery of Novel E3 Ligase Binders via Rapid Screening of DNA-Encoded Libraries

- DNA-encoded library technology enabled the identification of novel binders for buckets of E3 ligases in a cost-efficient way
- Examples of potent binders for both ubiquitous E3 and tissue specific E3 Ligases directly from DEL
- Refined workflow towards ligase binder and PROTAc discovery at GSK

12.30 Lunch Break

Unearthing New Opportunities in Indications & Modalities with Tailored Assay & Screening Design to Create New Avenues for Your Candidate

Ankit Sharma
Associate Director, Medicinal Chemistry, Oncology Targeted Discovery
AstraZeneca

1.30 Optimizing Proteolysis Targeting Chimeras (PROTACs) for Oral Drug Delivery NEW DATA

- Outlining our approach towards target selection
- Defining the key principles that govern oral absorption for bRo5 compounds
- Extrapolating trends and conclusions drawn from the data analysis of AZ compounds

Diogo Feleciano
Co-Founder & Chief Scientific Officer
Booster Therapeutics

2.00 A Novel Protein Degradation Modality to Address Multiple Diseases NEW DATA

- Screening and discovery of new small molecules to promote protein degradation
- Unique protein degradation modulation that holds promise as a new therapeutic approach
- Proof-of-concept data in an animal disease model

2.30 Afternoon Break & Networking

REGISTER NOW

TPD Assay Development & Screening Focus Day
Monday, October 28 2024

7th Annual TPD & Induced Proximity Summit
October 28 - 31 | Boston, MA

Advancing New Ligase & New Ligand Understanding with Novel *In Vitro* & *In Vivo* Assay Design to Expand the Therapeutic Potential

Ryan Kerrigan
Principal Scientist II
Novartis

3.00 **Discovery & Optimization of First-in-Class Molecular Glue Degraders of the WIZ Transcription Factor for Fetal Hemoglobin Induction to Treat Sickle Cell Disease**

- A phenotypic screen identified inducers of fetal hemoglobin to treat SCD
- Subsequent target elucidation identified CRBN dependent degradation of the transcription factor WIZ as driver of HbF induction
- Med chem optimization resulted in molecules with improved WIZ degradation selectivity and *in vivo* PK/PD and efficacy and candidates for development

Xiaoran Han
Vice President Discovery Medicine
Cullgen

3.30 **Discovery of Novel E3 Ligands for Targeted Protein Degradation**

- Uncovering the catalytic mechanism to achieve higher efficacy, the ability to target previously undruggable proteins and the potential to deliver drug activity to selective tissues in TPD
- Demonstrating how E3 ligands hold the key to realize the full potential of TPD but are currently limited
- Discussing our rationale and efforts in discovering novel E3 ligands for targeted protein degradation

Gary Kleiger
Chair and Professor
University of Las Vegas Nevada

4.00 **Robust Cullin-RING Ligases Employ Geometrically Optimized Catalytic Partners for Substrate Targeting**

- Cullin-RING ligases collaborate with multiple distinct E2s and the ARIH1 ubiquitin ligase to efficiently target thousands of protein substrate for ubiquitylation
- What *in vitro* assays demonstrate high predictive value towards degrader drug efficacy? How can this be optimized?
- Does *in vitro* ubiquitin ligase efficiency correlate with cellular neo-substrate degradation?

Abhishek Dogra
Director Medicinal Chemistry & Induced Proximity
A-Alpha Bio

4.30 **Chair's Closing Remarks**

4.45 **End of TPD Assay Development & Screening Focus Day**

"The TPD & Induced Proximity Summit is an information rich conference"
Vice President Chemistry, Ambagon

REGISTER NOW

TPD & Induced Proximity 101 Bootcamp Day

LIMITED PASSES REMAINING

Monday, October 28

Key Agenda Highlights:

Discovery & Development of Small-Molecule Glue Degraders of KRAS G12D as the First-in-Class Anticancer Drugs

Anita C. Bellail, Chief Scientific Officer & Co-Founder, **HB Therapeutics**

ASGPR vs M6PR: Common & Orthogonal Applications for Extracellular Protein Degradation

Effie Tozzo, Chief Scientific Officer, **Avilar Therapeutics**

"Excellent content & diversity of speakers"
Senior Scientist, Blueprint Medicines

The field of TPD & Induced Proximity is expanding rapidly, with more investment and companies entering the space year-on-year. Recent deals between **ADCs and TPDs to create DACs** have highlighted the immense potential of combining modalities with degraders.

In this session, uncover the **fundamental principles underpinning** targeted protein degradation and induced proximity. Whether you're a senior scientist **entering a TPD team for the first time**, or director of a biotech thinking of **moving into the TPD** space, this day will give you the essential knowledge and insights to build a solid **foundation** of understanding before diving into the industry's pipeline updates in the subsequent days.

9.00 AM Session

- Introducing the fundamental principles of targeted protein degradation & induced proximity
- Harnessing protein degradation to drug the undruggable
- Structure & regulation of the proteasome
- Novel E3 ligase-based targeted protein degradation: potential applications within & beyond cancer therapy

12.30 Networking Lunch Break

1.30 PM Session

- Discovery & development of small-molecule glue degraders of KRAS
- Common & orthogonal applications for extracellular protein degradation

abbvie · Avilar THERAPEUTICS · HARVARD UNIVERSITY · NOVARTIS

CONTENTS

REGISTER NOW

TPD & Induced Proximity 101 Bootcamp Day
Monday, October 28 2024

7th Annual TPD & Induced Proximity Summit
October 28 - 31 | Boston, MA

8.00 **Check-in & Morning Coffee**

Ethan Toriki
Discovery Postdoctoral Fellow
Novartis

8.45 **Chair's Opening Remarks**

Introducing the Fundamental Principles Underpinning Targeted Protein Degradation & Induced Proximity to Jump-Start Your Degrader Program

William Housley
Principal Research Scientist
AbbVie

9.00 **Harnessing Protein Degradation to Drug the Undruggable: The History & Promise of Targeted Protein Degradation**

- The field of targeted protein degradation has rapidly expanded to offer the potential to drug targets that were previously considered undruggable
- PROTACs, MoDEs, and molecular glues have led the way into clinical trials and have shown promise for durable, effective therapeutics in cancer and other indications
- Multiple new targeted protein degradation modalities have been developed in the preclinical space that may allow targeting signaling pathways, cell types and tissues that were previously thought to be difficult to drug

Dan Finley
Professor
Harvard Medical School

9.30 **Structure & Regulation of the Proteasome**

- The proteasome degrades ubiquitinated proteins by unfolding them and translocating them into a proteolytic chamber
- The proteasome is regulated by numerous cofactors, among them substrate delivery factors, inhibitors, deubiquitinating enzymes, protein kinases, ubiquitin ligases, and assembly chaperones
- Whether a ubiquitinated protein is a good proteasome substrate depends on multiple features, a major one being the presence of an "initiation element" that is is critical for effective unfolding

Katie Spooner
Research Analyst
Beacon

10.00 **A Landscape Review of TPD-Based Drug Development**

- An overview of the drug & trial landscape
- A recap of the developments in 2024 so far
- Insights into novel degraders & a look to the future

10.20 **Morning Break & Networking**

REGISTER NOW

TPD & Induced Proximity 101 Bootcamp Day

Monday, October 28 2024

7th Annual TPD & Induced Proximity Summit

October 28 - 31 | Boston, MA

Meet the E3 Ligase Family: Understanding this Protein's Role in Protein Degradation & Development into Therapeutics

Hailong Zhang
Chief Executive Officer
Blueray Biopharma

11.30 **Novel E3 Ligase-Based Targeted Protein Degradation: Potential Applications Within & Beyond Cancer Therapy**

- Somatic mutation of some E3 ligases create novel E3 ligase that are not exist in normal tissues
- Targeted protein degradation using the mutated E3 ligases are very specific and only happen with the presence of the mutated E3 ligase
- Novel E3-based TPD and potential applications are discussed with an example

Ethan Toriki
Discovery Postdoctoral Fellow
Novartis

12.00 **Gluing the Pieces Together, to Break it All Down: Harnessing Novel E3 Ligases for Molecular Glue Degraders**

NEW DATA

- The TPD field currently lacks rational chemical design principles for converting protein-targeting ligands into molecular glues
- Using known protein binders, we sought to identify transposable motifs which would convert these ligands into protein degraders
- RNF126, a previously unliganded RING E3 ligase, was determined to be an amenable ligase mediating a multitude of neo-substrate recognition events, leading to the discovery that it could be harnessed in a protein complex and act as an effective ubiquitinating and degrading chaperone

12.30 **Networking Lunch Break**

Charu Chaudhry
Associate Director
Johnson & Johnson Innovative Medicine

1.30 **Roundtable Discussion: Expanding E3 ligase Platforms for Targeted Protein Degradation**

- Current state of the art, selection of Next-Gen E3 ligases and winning screening strategies, e.g. Rational design Hit ID, phenotypic function 1st, computational AI-ML
- Accelerated workflows for binder to degrader conversion
- Tissue- specific and tissue restricted TPD : has this underdelivered and what are the main obstacles ?
- Expanding molecular glue potential of E3 ligands

Anita C. Bellail
Chief Scientific Officer & Co-Founder
HB Therapeutics

2.00 **Discovery & Development of Small-Molecule Glue Degraders of KRAS G12D as the First-in-Class Anticancer Drugs**

- Cancer cell-based drug screening identified hit compounds that abide Lipinski rule and degrade active GTP KRAS G12D protein in KRAS G12D mutated cancer cells
- High-throughput technologies revealed a novel E3 ligase and mechanism of drug action in which degraders bind the E3 ligase and KRAS G12D and induce the KRAS degradation
- Protein structure-guided and AI-powered drug design speeded up hit to lead optimization for identification of preclinical candidates as the first-in-class anticancer drugs

REGISTER NOW

TPD & Induced Proximity 101 Bootcamp Day
Monday, October 28 2024

7th Annual TPD & Induced Proximity Summit
October 28 - 31 | Boston, MA

Unleashing the Full Potential of Protein Degradation Machinery with New Applications

2.30 **Afternoon Break & Networking**

3.00 **Molecular Glues for Target Protein Degradation**

Kelly Rainbolt
Senior Scientist
Lyterian Therapeutics

- Emerging themes in molecular glue degrader mechanisms
- How molecular glue degraders are advancing as therapeutics
- Moving from serendipitous discovery to rationale design

3.30 **ASGPR vs M6PR: Common & Orthogonal Applications for Extracellular Protein Degradation**

Effie Tozzo
Chief Scientific Officer
Avilar Therapeutics

- Review of two endocytotic cell surface receptors, ASGPR and M6PR, and their uses for degrading soluble circulating and membrane proteins
- Novel proprietary ligands for ASGPR and M6PR as backbones for ATAC (ASGPR Targeting Chimeras) and MTAC (M6PR Targeting Chimeras) degraders
- *In vitro* and *in vivo* protein degradation studies comparing ATACs vs MTACs and therapeutic implications

4.00 **Chair's Closing Remarks**

Charu Chaudhry
Associate Director
Johnson & Johnson Innovative Medicine

4.15 **End of TPD 101 Bootcamp Day 2024**

"A new area to me so good to get a spread of talks across different aspects of TPD!"
Director, Innovation Hub Biology, Bicycle Therapeutics

REGISTER NOW

Novel Technologies to Accelerate TPD Discovery Workshop Day

LIMITED PASSES REMAINING

Monday, October 28

> Great workshops & learning opportunities for people new to the area!
>
> **Associate Principal Scientist, Merck & Co.**

6
Hours of Deep-Dive Discussion-Based Content!

Ever have a question for the presenter that you are just itching to ask but have to wait until the end of the talk? Not in these sessions.

Built with a focus on uncovering new technologies, unraveling how they work, and applying this to your degrader discovery and development, our **3 workshops** allow attendees to **interact**, **discuss**, and **collaborate** in deep-dive sessions with subject matter experts to unlock essential tools to accelerate your hit finding, validation, and compound optimization efforts.

Honing in on Three Key Areas:

- Integrating **structural dynamics** studies into TPD drug discovery using **SAR** & Time-resolved **Cryo-EM**

  Radoslav Enchev, Group Leader, **The Francis Crick Institute**

  Dmitri Ivanov, Associate Professor, **UT Health San Antonio**

- Optimizing **Physicochemical & ADME Properties** to Deliver **Orally Bioavailable PROTACs**

  Mark Niosi, Principal Scientist, **Pfizer**

  Sarah Carratt, Principal Scientist, **Pfizer**

- Introduction to **Computational Approaches** & the Implementation of **AI/ML Tools** to Realise the Full Potential of Targeted Protein Degradation

  Andrew Potterton, Head of Platform, **Ternary Therapeutics**

Attending the **Novel Technologies to Accelerate TPD Discovery Workshop Day** puts you in face-to-face discussion with like-minded peers determined to collaborate and share thoughts on how to utilize new tools and methods to advance degrader discovery and design.

CONTENTS

REGISTER NOW

Novel Technologies to Accelerate TPD Discovery Workshop Day

Monday, October 28 2024

7th Annual TPD & Induced Proximity Summit

October 28 - 31 | Boston, MA

8.30 Workshop A

Intergrating Structural Dynamics Studies into Drug Discovery

Integrating structural dynamics studies into drug discovery, particularly through advanced techniques like cryo-EM and time-resolved cryo-EM, provides detailed insights into the conformational changes and interactions within protein complexes.

Attend this workshop to:

- Overview of methods for observing ternary complex formation and their value for enabling SAR
- Focus on the unique advantages and challenges of cryo-EM and single particle analysis for leveraging conformational dynamics, specifically in the context of E3 ligases relevant to TP
- Discuss in depth time-resolved cryo-EM and its applications to merging quantitative biochemistry and structural biology for drug discovery
- Use high-purity FRET-active E2~Ub conjugates for monitoring degrader-mediated protein ubiquitylation in single-step FRET assays

Radoslav Enchev, Group Leader, **The Francis Crick Instutute**

Dmitri Ivanov, Associate Professor, **UT Health San Antonio**

11.30 Workshop B

ADME / Safety Challenges for Degraders to Deliver Orally Bioavailable PROTACs

A significant challenge with oral bioavailability for large and complex molecules like PROTACs, lies in their propensity to experience poor intestinal absorption. Factors such as low membrane permeability, instability within the intestinal environment, and susceptibility to enzymatic degradation, all can hinder their ability to be orally bioavailable.

Attend this workshop to:

- How useful are ADME properties for design and optimisation of PROTACs
- Opportunities of different analytical and in silico tools to advance drug design
- Identify and resolve the challenges within in vitro ADME assays in drug discovery (DDI, PPB, Metabolic stability etc)
- In vitro safety challenges can be addressed with in vitro assays, when paired with proteomics, in vitro models have utility in identifying relevant species for toxicology studies and predicting toxicity prior in animal studies

Mark Niosi, Principal Scientist, **Pfizer**

Sarah Carratt, Principal Scientist, **Pfizer**

2.30 Workshop C

Introduction to Computational Approaches & the Implementation of AI/ ML Tools to Realise the Full Potential of Targeted Protein Degradation

Effectively visualizing and interpreting insights from huge datasets can be difficult, as traditional tools may struggle with scale, and identifying meaningful patterns requires sophisticated analytical techniques.

Attend this workshop to:

- Acquire an expert introduction of computational tools used in degrader discovery
- Harness an overview of the tools to predict ternary complex modeling, a key stage in protein degradation
- Apply Machine Learning to advance your own degrader pipeline

Andrew Potterton, Head of Platform, **Ternary Therapeutics**

10.30 Morning Break & Networking

1.30 Networking Lunch Break

4.30 End of Workshop Day 2024

REGISTER NOW

7th Annual

TPD & Induced Proximity Summit

Industry Day One

Tuesday, October 29

KEYNOTE SESSION:

CEO Think Tank

John Houston
Chairperson, President & Chief Executive Officer
Arvinas

Adrian Gottschalk
Chief Executive Officer
Foghorn Therapeutics

Nello Mainolfi
Founder, President & Chief Executive Officer
Kymera Therapeutics

Arthur Sands
Chief Executive Officer
Nurix Therapeutics

MORNING PLENARY SESSIONS

- Visions for the Future of TPD & Beyond: The CEO Perspective

DISCOVERY TRACK

- From Sequence to Glue: A Multi-Dimensional Journey in the Embedding Space
- Rational Design of Selective MGDs

PRECLINICAL TRACK

- An Orally Bioavailable, Oncogenic Mutant-Selective Degrader with CNS Exposure & Activity for the Treatment of Naive & Treatment-Resistant Solid Tumors
- Discovery of GLB-003, A Potent, Selective, & Orally Bioavailable Bifunctional Degrader of Wee1 for the Treatment of Advanced Solid Tumors

CLINICAL TRACK

- Targeting 'Undruggable' Targets: Pioneering Novel Applications of Heterobifunctional Degraders
- Targeted Protein Degradation & The Chromatin Regulatory System

ANNUAL TPD AWARDS & DRINK RECEPTION

Annual TPD & Induced Proximity Awards 2024

CONTENTS

REGISTER NOW

Industry Day One | Tuesday October 29, 2024

7th Annual TPD & Induced Proximity Summit

October 28 - 31 | Boston, MA

MORNING KEYNOTE PLENARY SESSION

7.00 Check-In & Morning Coffee

Alessio Ciulli
Director of the Centre for Targeted Protein Degradation
University of Dundee

8.15 **Honorary Opening Remarks**

Visions for the Future of TPD & Beyond: The CEO Perspective

Chair: Neil Torbett, Chief Executive Officer, **Phoremost**

Moderator:

Ryan Cross
Senior Science Correspondent
Endpoints News

Nello Mainolfi
Chief Executive Officer
Kymera Therapeutics

8.30 **Fireside Chat: TPD - Where Are We Now & Where Are We Going?**

A sit down conversation with **Kymera Therapeutics' Chief Executive Officer**, **Nello Mainolfi** on his thoughts on strategy, current roadblocks, and future directions for the targeted protein degradation field

Moderator:

Ryan Cross
Senior Science Correspondent
Endpoints News

John Houston
Chairperson, Chief Executive Officer, & President
Arvinas

9.00 **A Presentation on Arvinas' State-of-Play & Fireside Chat**

A sit down conversation with **Arvinas' Chief Executive Officer, John Houston** on his thoughts on strategy, current roadblocks, and future directions for the targeted protein degradation field

9.30 **CEO Think Tank: A Strategic Look at Targeted Protein Degradation & Induced Proximity Field**

- Assessing what we are learning from clinical candidates
- Considering pipeline prioritization for mid to large biotechs progressing multiple programs
- Advice to fledging biotechs on advancing through discovery and enabling clinical success

Moderator:

Neil Torbett
Chief Executive Officer
Phoremost

Panelists:

Arthur Sands
President & Chief Executive Officer
Nurix Therapeutics

Adrian Gottschalk
President & Chief Executive Officer
Foghorn Therapeutics

Andrew Hirsch
President & Chief Executive Officer
C4 Therapeutics

Industry Day One | Tuesday October 29, 2024

MORNING KEYNOTE PLENARY SESSION

10.00 Panel Discussion: How Are Regulators, Industry & Academia Thinking About Degraders from a Safety Perspective in 2025?

- What if anything has changed on the FDA side with regards regulation of degraders?
- What is the pre-clinical and clinical data telling us thus far for degraders?
- Where are the opportunities for collaboration between stakeholders to drive these needs forward?

Moderator:

Raegan O'Lone
Senior Program Advisor
HESI

Panelists:

Stephanie Leuenroth-Quinn
Pharmacologist
FDA

Brad Heckmann
Chief Scientific Officer
Asha Therapeutics

Shyra Gardai
Chief Scientific Officer
EpiBiologics

Zoran Rankovic
Director, Centre for Protein Degradation
The Institute for Cancer Research

10.30 Morning Break & Speed Networking

With an international gathering of TPD & Induced Proximity experts, this valuable session will ensure you can reconnect with your peers in the room to make new and lasting connections. All attendees will have the opportunity to meet and network with their academic and industry colleagues!

> "Four days of high value content and engaging speakers and moderators - a must for those invested in the field of targeted degradation"
>
> **Associate Director, Novartis**

Industry Day One | Tuesday October 29, 2024

7th Annual TPD & Induced Proximity Summit

October 28 - 31 | Boston, MA

TRACK A: DISCOVERY | TRACK B: PRECLINICAL | TRACK C: TRANSLATIONAL/ CLINICAL

Accelerating the Rational Discovery & Design of Molecular Glues

Chair: Harris Bell-Temin, Director - Proteomics, **Johnson & Johnson Innovative Medicine**

11.30 From Sequence to Glue: A Multi-Dimensional Journey in the Embedding Space

- Using ML and data augmentation to combine disparate datasets
- Finding the most suitable E3 ligases to degrade your target
- Rational design of molecular glues using machine learning

NEW DATA

Arnout Schepers, Chief Executive Officer, **TenAces Biosciences**

12.00 Deep Proteomic Screening for Systematic Identification of Novel Degrader Targets

- High throughput proteomics quickly creates broad pipelines of novel, high-value degrader targets at scale and advances TPD drug discovery programs at all stages
- Comprehensive proteomics characterizes all types of protein degraders and stabilizers in native cells and identifies molecules that act through new E3 ligases and novel TPD mechanisms
- Global ubiquitinomics mechanistically validates target candidates and confirms degrader induced modifications to an unparalleled depth of 50,000 ubiquitination sites
- Intuitive data analysis applications visualize large proteomics datasets for immediate access, enabling informed decisions in drug discovery, SAR optimization, target identification, and library expansion

Henrik Daub, Founder & Chief Scientific Officer, **NEOsphere Biotechnologies**

12.30 Networking Lunch Break

Accelerating the Rational Discovery & Design of Molecular Glues

1.30 Rational Design of Selective CDK2 & Cyclin E1 MGDs

- Targeting Cyclin E1 or CDK2 by molecular glue degraders has therapeutic potential in cancers with cell-cycle pathway dysregulation, including breast, ovarian, endometrial, and gastric cancers
- Using a combination of experimentational data and ML algorithms, we have identified and optimized molecular glue degraders that selectively target either Cyclin E1 or CDK2 and robustly suppress downstream pathways and cell proliferation
- When used in in vivo tumor models as a single agent and in combination, these compounds induce strong tumor growth suppression and even regression

Nina Ilic-Widlund, Director - Oncology, **Monte Rosa Therapeutics**

2.00 A Novel Luciferase Reporter System to Monitor Targeted Protein Degradation

- PROTACs and molecular glues offer transformative potential for undruggable targets
- A New TUBE - LuxSit™ Pro luciferase platform to monitor in-situ ubiquitination of targets for PROTAC and Molecular glue drug discovery
- The new luciferase technology platform is superior to traditional methods to establish the relationship between ubiquitination and degradation of drug targets and advancing discovery of next-generation PROTACs and TPD medicines

Karteek Kadimisetty, Director R&D, **LifeSensors**

2.20 To Degrade or Not to Degrade - Solutions to Improve Discovery & Development

- Showcasing comprehensive solutions in the induced proximity space from discovery to development
- Developing multiple platforms including biophysical, cellular, target engagement, PK-PD correlations, Met-ID, animal efficacy, and safety
- Overcoming key challenges with customized solutions in different drug modalities in this space including proteasomal, lysosomal mediated degraders, conjugates, and stabilizers

Atul Tiwari, Vice President - Discovery Strategy, **Sai Life Sciences**

2.30 Integrating AI technology with Physics-Based Approach to Consider Thermodynamic Cycles of Ternary complex Formation for Molecular Glue Discovery

- Maximizing the power of in silico screening by combining AI approach and advanced computational screening methods
- Utilizing thermodynamic principles to predict ternary complex structures important for molecular glue discovery
- Emphasizing the exploration of novel E3 binders to overcome current limitations in Cereblon-based molecular glue degrader discovery

Keunsoo Kang, Co-Founder & Chief Scientific Officer, **Deargen Inc**

3.00 Afternoon Break & Poster Session

Advanced Platforms for Discovering Novel E3 Ligands & E3 Ligases Rapidly

4.00 From a Needle in a Haystack to a Haystack of Needles: A Systematic Approach for Molecular Glues Discovery

- Introducing our holistic approach to expand the scope of TPD by tapping in the vast E3 ligase space
- Showcasing the ability of our platform to identify to Molecular Glue degraders for undruggable targets

Amine Sadok, Director, Induced Proximity Platform, **Amgen**

4.30 Harnessing Large-Scale Protein-Protein Interaction Data to Reveal Gluable E3 Ligase & Neo-Substrate Pairs

- Measuring millions of protein-protein interactions (PPIs) between ligases and neosubstrates enables identification of basal interactions that can be enhanced using a small molecule
- By analyzing how specific mutations at the interaction interface modulate binding, we can create putative structural models of E3 ligases and neosubstrates through the refinement of AlphaFold multimer predictions
- Applying machine learning models to PPI datasets involving known linear degrons of E3 ligases and thousands of synthetic variants enables the prospective identification of neo-substrates across the human proteome

Randolph Lopez, Chief Technology Officer, **A-Alpha Bio**

5.00 Cracking the Molecular Glue Puzzle

- Presenting a systematic approach to discover monovalent molecular glues for any target and in any induced proximity modality
- Key aspects of cellular assays, large scale automation and advanced numerical modeling will be presented
- Several examples of novel discoveries will also be discussed

Riccardo Sabatini, Chief Data Scientist, **Orionis Biosciences**

REGISTER NOW

Industry Day One | Tuesday October 29, 2024

7th Annual TPD & Induced Proximity Summit

October 28 - 31 | Boston, MA

TRACK A: DISCOVERY | **TRACK B: PRECLINICAL** | TRACK C: TRANSLATIONAL/ CLINICAL

Unearthing Brand New Bifunctional Modes of Action & Achieving Potent, Selective ADME Preclinically

Chair: Zoran Rankovic, Director, Centre for Protein Degradation, **The Institute for Cancer Research**

11.30 An Orally Bioavailable, Oncogenic Mutant-Selective Degrader with CNS Exposure & Activity for the Treatment of Naive & Treatment-Resistant Solid Tumors

- Nurix has developed a pan-mutant selective degrader that can target naïve and treatment-resistant solid tumors
- Degraders active in primary and metastatic CNS disease were developed by incorporating brain penetrance as a key selection criteria in the program's testing funnel
- Potent anti-tumor activity in multiple CDX and PDX disease models, including treatment-resistant and CNS models, suggests the potential utility of these degraders across a broad range of solid tumor types

Ya-Wen Lu, Associate Director Cell Biology, **Nurix Therapeutics**

12.00 Divide-&-Conquer: Middle Down MS for Characterizing Target Sites of Covalent Fragments

- Digestion of target-ligand conjugates with trypsin followed by MS/MS can be successfully used to characterize fragment hits
- This approach often does not provide full sequence coverage and is subject to confounding effects of missed cleavage and variable oxidation
- Showcasing an alternatively, middle-down approach whereby conjugates are subject to limited digestion followed by complementary CID and EAD fragmentation on the ZenoTOF 7600 platform to map binding sites for covalent fragments

Jarrod Marto, Principal Investigator, **Dana-Farber Cancer Institute**

12.30 Networking Lunch Break

1.30 Developing Optimized Folding Interfering Degraders Targeting Cyclin D1

- Providing an overview of folding interference as a new modality to induce the degradation of a target protein
- Demonstrating that folding interfering degraders (FIDs) can be optimized to achieve high potency and desirable ADME properties
- Showing *in vitro* and *in vivo* characterization of FIDs acting on Cyclin D1

Giovanni Spagnolli, Chief Technology Officer, **Sibylla**

NEW DATA

2.00 Scale Up Your DC50 Curves: Meet Leo, a High Throughput Quantitative Capillary Western System

- Discussing Bio-Techne's TPD portfolio, and showcasing a brand new Simple Western™ Instrument, Leo™ System, a cutting-edge automated capillary immunoassay platform capable of fully automated analysis of protein expression in 96 lysate samples in 3 hours, so you can run quantitative degradation curves in a fraction of the time to help you accelerate your TPD workflows.

Chris Heger, Director - Applications Science, **Bio-Techne**

2.30 Discovery of First-in-Class PDE4D Bifunctional Degraders for Atopic Dermatitis

- Utilizing our proprietary PRODEGY discovery platform, we have designed potent and selective PDE4D bifunctional degraders
- Broad downregulation of cytokines produced by activated T cells
- A potent, specific, and safe PDE4D degrader as novel therapy for inflammatory skin diseases, such as atopic dermatitis

Arvind Shakya, Director Biology, **Biotheryx**

NON-ONCO

3.00 Afternoon Break & Poster Session

The poster session offers a dynamic platform for researchers and industry professionals to present their latest findings and innovations in a visually engaging format. Attendees can interact directly with presenters, fostering in-depth discussions, networking, and the exchange of ideas on a wide range of cutting-edge topics within TPD.

In Vivo Efficacy & Safety Data of Preclinical Binfunctionals

4.00 Discovery of GLB-003, A Potent, Selective, & Orally Bioavailable Bifunctional Degrader of Wee1 for the Treatment of Advanced Solid Tumors

NEW DATA

- Wee1 is a clinically validated target for many solid tumor indications
- Discovery of highly potent and orally bioavailable Wee1 bifunctional degrader
- Superior potency and drug-like properties of GLB-003, suggests the potential intermittent dosing regimen in clinical studies for better therapeutic index than Wee1 inhibitors

Leo Fu, Co-Founder & Chief Technology Officer, **GluBio Therapeutics**

4.30 The Transformative Power of PK/PD-Model Guided Optimization of TPDs in Translating *In Vitro* Data to Efficient Degradation Profiles *In Vivo*

NEW DATA

- Demonstrating how mechanistic PK/PD modeling can profoundly enhance the characterization and optimization of TPDs, and how *in vivo* degradation profiles can be predicted a priori based on *in vitro* data to tailor and interpret animal PD studies
- Illustrating the deconvolution of target degradation and target inhibition in the overall pharmacodynamic response, the quantitative role of target occupancy as well as expected and unexpected changes related to the unique mode-of-action after repeated dosing of TPDs
- Exemplifying best-practice applications of PK/PD modeling for compound selection and progression, and the generation of a translational understanding and strategy for targeted protein degradation

Andreas Reichel, Vice President Head of Preclinical Modelling & Simulations, **Bayer AG**

5.00 Chair's Closing Remarks

5.30 Annual TPD & Induced Proximity Awards & Drinks Reception

CONTENTS

Industry Day One | Tuesday October 29, 2024

TRACK A: DISCOVERY | TRACK B: PRECLINICAL | TRACK C: TRANSLATIONAL/ CLINICAL

Preclinical Profiles & Enabling Smooth, Efficacious Translation of Bifunctionals to Clinic

Chair: Charu Chaudhry, Associate Director, **Johnson & Johnson Innovative Medicine**

11.30 Clinical Insights on Leveraging Kinetics-Based PKPD Modeling to Drive Degrader Optimization

- Kinetics based PKPD modeling approaches can predict *in vivo* performance
- Correlation of preclinical model data to clinical response
- Leveraging clinical data to improve model performance and degrader optimization strategies

Stewart Fisher, Chief Scientific Officer, **C4 Therapeutics**

12.00 Targeting SWI/SNF Complex by SMARCA2/4 Degraders as Potential Therapies for Cancer Patients

- First-in-human SMARCA2 selective degrader PRT3789 Phase I clinical development
- Discovery of orally bioavailable SMARCA2 selective degrader PRT7732
- Potential use of SMARCA2/4 degrader-based ADCs to target SWI/SNF dependent cancers

Peggy Scherle, Chief Scientific Officer, **Prelude Therapeutics**

12.30 Networking Lunch Break

1.30 Degradation of Nuclear Receptors for Oncology: Advances in AR degrader HP518 & ER degrader HP568

- HP518 is in phase I/II clinical trial, showed satisfactory safety profile and sign of efficacy
- HP568 showed excellent preclinical PK and efficacy profile, superior to approved SERD drugs and leading ER PROTAC degrader ARV-471
- HP518 and HP568 are potential best in class AR and ER degraders

NEW DATA

Wu Du, Senior Vice President, **Hinova Pharmaceuticals**

Preclinical Profiles & Enabling Smooth, Efficacious Translation of Molecular Glues to Clinic

Chair: Yao Wang, Chief Medical Officer, **Kangpu Biopharmaceuticals**

2.00 Ultra-High-Throughput Miniaturized Cell-Based Assays to Discover Molecular Glue Degraders of IKZF2 & CDK2

- Overview of Plexium's bead DEL screening platform to identify cell-active cereblon degraders
- Update on PLX-4545, a selective IKZF2 molecular glue degrader in clinical studies
- Discovery of highly selective CDK2 molecular glue degrader

JF Brazeau, Director, **Plexium**

2.30 Inactivating SARM1 & Axonal Degeneration Using a Novel Intra-Molecular Glue

- Design of a novel intra-molecular glue small molecule to restore inactive protein conformation
- Predictive PK and safety during design results in a robust clinic-ready molecule
- Disease modifying efficacy of the intra-molecular glue in ALS

NON-ONCO

Brad Heckmann, Chief Scientific Officer & Co-Founder, **Asha Therapeutics**

3.00 Afternoon Break & Poster Session

The poster session offers a dynamic platform for researchers and industry professionals to present their latest findings and innovations in a visually engaging format. Attendees can interact directly with presenters, fostering in-depth discussions, networking, and the exchange of ideas on a wide range of cutting-edge topics within TPD.

Optimizing Pipeline Strategy & Asset Management to Guide Effective Translation to Clinic

4.00 Targeting 'Undruggable' Targets: Pioneering Novel Applications of Heterobifunctional Degraders

- How Astellas identified, and is executing, a long-term innovation strategy in Targeted Protein Degradation
- Learnings from the discovery and development of ASP3082
- Accelerating our progress through an integrated approach to in-house R&D, translational research and innovation partnering

Chinatsu Sakata-Sakurai, Vice President, Primary Focus Lead, Targeted Protein Degradation, **Astellas**

4.30 Targeted Protein Degradation & The Chromatin Regulatory System

- Expanding delivering optionality for degrader program
- Recent developments from Foghorn's degrader pipeline

Steven Bellon, Chief Scientific Officer, **Foghorn Therapeutics**

5.00 Chair's Closing Remarks

5.30 Annual TPD Awards & Drinks Reception

REGISTER NOW

7th Annual

TPD & Induced Proximity Summit

Industry Day Two

Wednesday, October 30

KEYNOTE SESSION:

3.25 | **Preparing for the Future: Strategy, Partnering & Investment for TPD & Beyond**

Scott Boyle
Chief Business Officer
C4 Therapeutics

Randy Teel
Chief Business Officer
Arvinas

Barbara Lueckel
Global Head, Research Technologies Partnering, Pharma Partnering
F. Hoffmann-La Roche

MORNING PLENARY SESSIONS

NEW

- Clinical Disclosures from leading players in the TPD field

DISCOVERY TRACK

- Discovery of Novel Monovalent Degraders of SMARCA2/4
- Degrading Hard to Drug Disease Causing Extracellular Proteins

PRECLINICAL TRACK

- Discovery & Chemical Optimization of Molecular Glue Degraders
- Developing Orally Bioavailable PROTACs: What we Learned so Far

CLINICAL TRACK

- Exploring ADME Profiles for Disease & Drug Efficacy to De-Risk Clinical Trials
- Bolstering Formulation Knowhow to Deliver Candidate Compounds Effectively

CLOSING PLENARY SESSIONS

NEW

- Accelerating Investments, Partnering & Collaboration in TPD Field

CONTENTS

REGISTER NOW

Industry Day Two | Wednesday, October 30 2024

MORNING KEYNOTE PLENARY SESSION

7.15 Check-in & Morning Coffee

Nan Ji
Co-Founder, President & Chief Executive Officer
PAQ Therapeutics

8.15 **Chair's Opening Remarks**

Advancing Bifunctionals Towards the First Approval with Clinical Data from Leaders in Clinic

Len Reyno
Chief Medical Officer
C4 Therapeutics

8.30 **Initial Clinical Data From the Ongoing Clinical Trial of CFT1946**

- Well-tolerated at all dose levels; no dose-limiting toxicities
- Dose proportional pharmacokinetic exposure; successfully degrades BRAF V600 mutant protein
- Early evidence of CFT1946 monotherapy anti-tumor activity in patients who have progressed on or after BRAF inhibitor therapies
- Preclinical data demonstrating blood-brain barrier permeability

NEW DATA

Paula O'Connor
Chief Medical Officer
Nurix Therapeutics

9.00 **Clinical Activity of NX-5948 in CLL & NHL: A First-in-Class BTK Degrader**

- Emerging clinical data support utility of novel MOA against validated target
- Activity demonstrated in the CNS and in patients harboring BTKi resistance mutations

NEW DATA

Elizabeth Caine
Senior Research Scientist
Promega

9.30 **Enabling Insights into Molecular Glue MoA Toward Design of Potent & Selective CK1a Degraders**

- Understanding neosubstrate selectivity through degradation and ternary complex profiling of CRBN molecular glues
- Development of a potent CK1a-selective degrader guided by cellular degradation and ternary complex studies
- Correlating specific target degradation with cellular outcomes

Filip Janku
Chief Medical Officer
Monte Rosa Therapeutics

10.00 **Molecular Glue Degraders (MGDs) – From the Bench to the Clinic**

- MGDs discovered serendipitously have been limited in scope to heme oncology
- Monte Rosa's Queen™ platform allows identification of highly selective and oral MGDs that go beyond heme oncology into solid tumors and non-oncology indications, as illustrated by our GSPT1 and VAV1 programs

10.30 Morning Break & Networking

TRACK A: DISCOVERY | TRACK B: PRECLINICAL | TRACK C: TRANSLATIONAL/ CLINICAL

Novel Target & Pathway Identification & Selection to Unearth New Molecular Glues

Chair: Leo Fu, Co-Founder & Chief Technology Officer, **GluBio Therapeutics**

11.30 Novel Molecular Glue Targets

- A key question to address is "are there translatable structural degron's in molecular glue targets (like the -hairpin) for E3 ligases/presenters beyond CRBN?
- We will highlight some successful approaches taken at Novartis to identify novel molecular glue targets
- Selected examples of novel molecular glue targets will be shown for non-CRBN based presenters

Gregory Michaud, Director, **Novartis**

12.00 First-in-Class Molecular Glue Degrader of an RNA-Binding Protein to Treat BRAF-Mutant Tumors

- Identifying a degrader of a previously undruggable RNA binding protein (RBP) using proteomic screen of Degron glue libraries
- Leveraging a preclinical candidate (PCC) with potent oral activity, identified through SAR
- Demonstrating efficacy with PCC compound inhibited growth of BRAF-mutant CRC by degrading the RBP

NEW DATA

Yong Cang, Chief Scientific Officer & Co-Founder, **Degron Therapeutics**

12.30 DEL Facilitates the Discovery of TPD Molecules

- Comprehensive tool box for the chemical inducer of proximity
- Applications of DNA-Encoded compound libraries (DEL) in the discovery of PROTAC and other "X-TAC" compounds
- Molecule Glue OBOC Selection

Zhifeng Yu, Director of Assay & DEL Screening, **WuXi Apptec**

12.50 Fast-Tracking MDM2: Efficient Expression & Purification of Active E3 Ubiquitin Ligase for Target Protein Degradation

- Securing adequate supply of functional recombinant E3 ligases is essential for advancing drug discovery. The eProtein Discovery System transforms cell-free protein production, enabling researchers to obtain high-quality proteins in just 2 days.
- Demonstrating a streamlined process for rapid expression and purification screening, which helps define the optimal conditions for producing MDM2 at high yields
- Functional validation with an autoubiquitination activity assay helps identify the best truncation for MDM2, allowing selection of construct for scale up production to accelerate drug discovery efforts

Michael Chen, Chief Executive Officer, **Nuclera**

13.00 Networking Lunch Break

Unravelling MOA & Optimizing Binding of Selective Degraders

Chair: Leo Fu, Co-Founder & Chief Technology Officer, **GluBio Therapeutics**

2.00 Discovery of Novel Monovalent Degraders of SMARCA2/4

- Using a library approach starting from a functionally inert SMARCA2/4 ligand, monovalent SMARCA2/4 degraders were identified
- The hits were optimized to potent and selective degraders that are on par in these aspects with reported bivalent degraders
- Mechanistic studies revealed that the CRL FBXO22 is responsible for the degradation with evidence of SMARCA2/FBXO22 ternary complex formation

Joachim Rudolph, Senior Fellow, **Genentech**

NEW DATA

2.30 Degrading Hard to Drug Disease Causing Extracellular Proteins

- Leveraging a new bispecific antibody technology to bind membrane and soluble targets
- Directing hard to drug surface and soluble targets to the proteosome and lysosome for degradation
- Unraveling deeper understanding of extracellular degraders to enable correct pairing with target proteins

Shyra Gardai, Chief Scientific Officer, **EpiBiologics**

NEW DATA

3.00 Afternoon Networking Break

Industry Day Two | Wednesday, October 30 2024

TRACK A: DISCOVERY | **TRACK B: PRECLINICAL** | TRACK C: TRANSLATIONAL/ CLINICAL

Novel Compound & MOA Discovery with PK Assessment to Enable Compound Chemistry Optimization

Chair: Giovanni Spagnolli, Chief Technology Officer, **Sibylla**

11.30 Discovery of Bifunctional Degraders Operating Through the CUL1/SKP1 SCF Complex

- Ligase discovery for TPD via phenotypic screening
- Novel mechanisms of degradation hijacking the CULLIN-1 ligase complex
- Discovery of novel E3 ligase chemistry for target protein degradation

Christian Dillon, Chief Scientific Officer, **PhoreMost**

NEW DATA

12.00 Discovery of a GRK2 Degrader for Potential Treatment of Heart Failure

- Discovery of an In vivo PROTAC tool degrader, demonstrating good exposure and high level of GRK2 degradation in rat hearts, suitable for target validation in rat efficacy studies
- Tuning of degradation assay as project progress improved SAR understanding
- Optimization of kinase selectivity and advantage of degradation vs inhibition

Johan Johansson, Associate Principal Scientist, CVRM PROTAC Lead, Project Leader, **AstraZeneca**

12.30 Ask the Speakers

Your unique opportunity to ask the speakers your burning questions from the previous sessions in a dedicated Q&A session

13.00 Networking Lunch Break

Harnessing Biochemical Techniques to Optimize Bi-functionals Preclinically

Chair: Giovanni Spagnolli, Chief Technology Officer, **Sibylla**

2.00 Discovery & Chemical Optimization of Molecular Glue Degraders

- Glue degraders against an undruggable target were discovered by ligase-agnostic phenotypic screening
- Chemical optimization resulted in orally bioavailable compounds with excellent ADME and PK profiles
- Dose-dependent tumor growth inhibition at tolerated doses was observed across multiple xenograft models

Matthias Brand, Chief Scientific Officer, **Proxygen**

NEW DATA

2.30 Developing Orally Bioavailable PROTACs: What we Have Learned so Far

- Design and characterization of orally bioavailable BRD4- and LCK-PROTACs
- Direct *in vitro/vivo* comparison of PROTACs containing the next generation CRBN-warheads
- Parameters critical to the development of orally bioavailable PROTACs

Zoran Rankovic, Director, Centre for Protein Degradation, **The Institute for Cancer Research**

3.00 Afternoon Break

REGISTER NOW

Industry Day Two | Wednesday, October 30 2024

TRACK A: DISCOVERY | TRACK B: PRECLINICAL | TRACK C: TRANSLATIONAL/ CLINICAL

Safety, Toxicology, & Clinical Efficacy of Degraders Progressing Through Clinic

Chair: Andreas Reichel, Vice President Head of Preclinical Modelling & Simulations, **Bayer AG**

11.30 Unearthing Clinical Findings from the Degrader KPG-121 in mCRPC:

- A potent CK1 degrader: Synergic effect was observed in preclinical studies
- Phase 1 clinical study demonstrates preliminary safety and efficacy
- Single patient expanded access program case report: overcome enzalutamide resistance

Yao Wang, Chief Medical Officer, **Kangpu Biopharmaceuticals**

NEW DATA

12.00 Discovery & Development of Novel CELMoD Molecular Glues & Ligand Directed Degraders for Oncology

- Description of the approaches within BMS on CELMoD molecular glues and ligand directed degraders, the way we find novel glue degraders and the compelling targets we're pursuing.
- Discussion on several of our novel heterobifunctional ligand directed degraders and CELMoD molecule glues from preclinical to clinical

Neil Bence, Vice President, Oncology Discovery, **Bristol Myers Squibb**

12.30 Collaborative Approaches to Advancing Integrated Safety Assessment of Targeted Protein Degraders

- Reviewing safety considerations for development of bivalent and monovalent protein degraders.
- Initiating wide multi-sector collaborative efforts to address cereblon-related safety challenges and study design challenges for safety assessment will be described
- Discussing needs and recommendations towards enhancing safety assessment of targeted protein degraders

Raegan O'Lone, Senior Program Advisor, **HESI**

13.00 Networking Lunch Break

Findings from Nonclinical Safety Assessments of Degraders to Enable Effective Progression to Clinic

Chair: Andreas Reichel, Vice President Head of Preclinical Modelling & Simulations, **Bayer AG**

2.00 Approaches to Species Selection & Off-target Assessment of Cereblon-Based Molecular Glue Degraders

- Leveraging computational toxicology and multi-omics analysis to accelerate profiling and de-risking of off-target degradation
- Approaches to non-clinical species selection to enable sufficient safety assessment of on and off-target neosubstrates
- Key challenges of developing an IND-enabling non-clinical safety package for a molecular glue degrader

Jessica Sims, Principal Scientist, **Genentech**

2.30 Nonclinical Safety Assessment of TPDs: Focus on Teratogenicity Evaluation for Cereblon-engaging Degraders

- Points to consider for nonclinical assessment of teratogenicity risk
- Scientific and regulatory aspects
- Case example of cereblon-engaging degrader

Lise Loberg, Research Fellow, **AbbVie**

3.00 Afternoon Networking Break

Industry Day Two | Wednesday, October 30 2024

CLOSING KEYNOTE PLENARY SESSION

Sean Zhu
Senior Director - Computational Chemistry
Kymera Therapeutics

3.30 **Structural, Biochemical, Biophysical, & Computational Characterization of KT-474**

- Heterobifunctional degrader KT-474 induces ternary complex formation, ubiquitination, and degradation of IRAK4
- Ternary complex structure shows novel protein-protein interactions important for ternary complex formation and stability
- Structural explanations for cooperativity and selectivity will be discussed

NEW DATA

Preparing for the Future: Accelerating Strategy, Partnering & Investment for TPD & Beyond

Katie Spooner
Research Analyst
Beacon

4.00 **A Review of the TPD Deals & Companies Landscape**

- An overview of the commercial landscape
- The 2024 deals & companies landscape
- Investment into novel degrader technologies

4.10 **Panel Discussion: Lessons Learned from a Major Strategic Partnership Deal for a Platform**

- Spotlighting some of the challenges and pitfalls when establishing a partnership
- Exploring the nuances of striking a deal for a discovery platform
- Zoning in on the opportunities created from a joint venture
- Considering how biotech can get the most out of an investment

Scott Boyle
Chief Business Officer
C4 Therapeutics

Bernd Boidol
Chief Executive Officer
Proxygen

Barbara Lueckel
Global Head, Research Technologies Partnering, Pharma Partnering
F. Hoffmann-La Roche

Jason Kantor
Chief Business Officer
Nurix Therapeutics

Scott Boyle
Chief Business Officer
C4 Therapeutics

4.45 **Introduction: A Review of the Current Trends in Asset Deals**

- 10-minute high level overview of the past and recent deals for early stage and later stage assets in TPD & Induced Proximity, for PROTACs, Molecular Glues, and beyond

4.55 **Panel Discussion: Lessons Learned from a Major Strategic Partnership Deal for an Asset**

- Spotlighting some of the challenges and pitfalls when establishing a partnership
- Exploring the nuances of striking a deal for a discovery platform
- Zoning in on the opportunities created from a joint venture
- Considering how biotech can get the most out of an investment

Scott Boyle
Chief Business Officer
C4 Therapeutics

Jason Kantor
Chief Business Officer
Nurix Therapeutics

Randy Teel
Chief Business Officer
Arvinas

CLOSING KEYNOTE PLENARY SESSION

Juliet Williams
Head of Research
Kymera Therapeutics

5.25 **Solving Big Problems with Small Molecule Degraders**

- To realize on the promise of this disease-agnostic technology, Kymera has taken a unique approach to target selection, where we focus on targets that are either undrugged or inadequately drugged within key signaling pathways with clear clinical validation and validation through human genetics/causal biology, and where TPD is the best or the only solution
- Our comprehensive drug discovery engine utilizes computational tools, fit-for-purpose technologies, and quantitative translational models to design potent and selective degraders and drive consistent fidelity of translation of safety, PK/PD, and early efficacy from preclinical models to patients
- Preclinical and early clinical findings across our immunology and oncology pipeline support a clear degrader advantage and our differentiated strategies to advance a new generation of medicines

Nan Ji
Co-Founder, President & Chief Executive Officer
PAQ Therapeutics

5.55 **Chair's Closing Remarks**

6.10 **End of Industry Day Two**

"In such a rapidly evolving field, it is crucial to have a touchpoint to check in on progress across companies. This is an excellent forum to meet the key players in the field and absorb new advances"

Senior Director of Chemistry, C4 Therapeutics

Next Generation Protein Modulation Focus Day
Thursday, October 31 2024

LIMITED PASSES REMAINING

7th Annual TPD & Induced Proximity Summit
October 28 - 31 | Boston, MA

8.00 **Check-In & Morning Coffee**

Benedict Cross
Chief Technology Officer
Phoremost

8.20 **Chair's Opening Remarks**

Innovating Techniques to Stabilize, Phosphorylate, & Degrade Intra & Extracellularly

Maureen Spit
Vice President Research
Laigo Bio

8.30 **SureTACsTM: Beyond Blocking Membrane Proteins**

- Membrane-bound E3 ligases can be repurposed for the targeted degradation of disease-driving cell surface proteins
- Laigo Bio's TED-I screening platform is essential to identify optimal E3-target pairs with highest degrader potency
- SureTACsTM: bispecific antibodies that induce cell surface removal and target degradation in a tissue- and disease-specific manner

Natalie Nairn
Co-Founder, Chief Executive Officer, & Chief Scientific Officer
Cyclera Therapeutics

9.00 **CYpHER: Catalytic Extracellular TPD for Potent Durable Effect in Oncology & CNS Disease**

- Engineering bispecific proteins that utilize transferrin receptor and pH-sensitive target binding to direct disease-driving proteins to the endolysosomal system
- Catalytic activity provides high potency and durability
- PD activity across mutational settings with superior activity and targeting versus traditional modalities

Jaehyun Choi
Chief Executive Officer
EPD Biotherapeutics

9.30 **Recent Progress in mRNA Based Targeted Protein Degrader Development**

- Update of EPDegTM bioPROTAC development
- Proved differentiating points of bioPROTAC platform from others
- Current challenges and future directions

Andrew Tsourkas
Professor
University of Pennsylvania

10.00 **Degradation of Key Intracellular Targets via the Cytosolic Delivery of Recombinant BioPROTACS**

NEW DATA

- Modification of antibodies and proteins with anionic polypeptides allows for complexation with cationic lipids and efficient intracellular delivery
- Recombinant BioPROTACS can be used to efficiently degrade "undruggable" intracellular targets
- Delivery of recombinant BioPROTACS may lead to significantly fewer differentially-regulated "off-target" proteins compared with mRNA encoded BioPROTACS

10.30 **Morning Break & Networking**

Introducing New Approaches to Stabilization of Targets to Induced Therapeutic Benefit

Kanak Raina
Senior Director Biology
Halda Therapeutics

11.30 **Advancing Oral RIPTAC™ Therapeutics Towards the Clinic**

- Novel heterobifunctional small molecule RIPTAC technology platform
- Leveraging protein-protein interactions and other mechanistic insights
- Halda's Prostate Cancer RIPTAC Program

CONTENTS

REGISTER NOW

Carolyn Porter
Chief Executive Officer
Outrun Therapeutics

12.00 **A Novel Approach to Targeted Protein Stabilization via E3 Ligase Inhibition**

- E3 ligase inhibition to stabilize proteins otherwise degraded in disease is an untapped therapeutic modality
- Introducing a novel platform for identification of direct inhibitors of E3 ligases and novel E3 ligases
- Selective and potent small molecule inhibitors of E3 ligases have been identified that stabilize tumour suppressor proteins and induce cell death in target tumour cell populations

12.30 **Networking Lunch Break**

Novel Takes on Molecular Glue Discovery & Development

Benedict Cross
Chief Technology Officer
Phoremost

13.30 **A Systematic Protein Editing Platform to Unlock Molecular Glue Discovery**

- Describing the challenges of monovalent drug discovery for induced proximity
- Introducing GlueSEEKER™, a new platform to enable MGD drug discovery
- Demonstration that E3 effector protein engineering can deliver neomorphic activity

Rick Ewing
Vice President Head of Chemistry
Rapafusyn

14.00 **Non-Degrading Molecular Glues: A Platform for Finding Novel Chemical Matter for Inhibiting Intracellular & Transmembrane Proteins**

- The described macrocycles form ternary complexes comprising a presenter protein (FKBP12), the molecular glue, and a target protein. Inhibition through formation of a ternary complex often results in potency, selectivity over homologous proteins and favorable drug like properties such as slow binding kinetics
- The construction of DEL and array libraries of molecular glues will be discussed as well as perspectives on topological diversity
- Screening of the platform has yielded chemical starting points have been discovered for several target classes. One program will described SAR leading to potent, cell permeable macrocycles for the inhibition of an oncology target. Another program will discuss the inhibition of a nucleoside transporter target that has yielded a development candidate

14.30 **Afternoon Break & Networking**

Pat Sharp
Senior Vice President Discovery Sciences
Gate Bioscience

15.00 **New Approach for TPD: Targeting the Secretory Translocon (Sec61) to Selectively Eliminate Extracellular Proteins**

- Mother Nature pioneered targeting of Sec61 for secretory protein degradation
- Selectivity is enabled by virtue of the unique sequences of Signal Peptides across the secretome
- Synthetic small molecules are capable of selectively eliminating secreted and membrane proteins

Elena De Vita
Assistant Professor
Queen Mary University of London

15.30 **PHOSTACs to Accelerate Targeted Protein Dephosphorylation**

- PHOSTACs state of the art and current challenges
- Targets and phosphatases for PHOTAC design
- Targeted covalent ligands for small molecule PHOSTACs

Maureen Spit
Vice President Research
Laigo Bio

16.00 **Chair's Closing Remarks**

16.15 **End of 7th TPD & Induced Proximity Summit 2024**

2024 Partners

Expertise Partner
Promega
www.promega.com

Program Partner
NEOsphere BIOTECHNOLOGIES
www.neospherebiotechnologies.com

Program Partner
SCIEX
www.sciex.com

Program Partner
biotechne
www.bio-techne.com

Program Partner
X-CHEM TAKE THE LEAD. DRIVE DISCOVERY.
www.x-chemrx.com

Innovation Partner
LifeSensors
www.lifesensors.com

Innovation Partner
药明康德 WuXi AppTec
www.wuxiapptec.com

Innovation Partner
Sai
www.sailife.com

Innovation Partner
BPG™ bio
www.bpgbio.com

Innovation Partner
nuclera
www.nuclera.com

Exhibition Partner
BIODURO-SUNDIA 保诺-桑迪亚
www.bioduro-sundia.com

Exhibition Partner
charnwood discovery
www.charnwooddiscovery.com

Exhibition Partner
revvity
www.revvity.com

Exhibition Partner
INTERPLAY BIO
www.interplay.bio

Exhibition Partner
NIS NANOIMAGING SERVICES
www.nanoimagingservices.com

CONTENTS

REGISTER NOW

2024 Partners

Exhibition Partner
www.seranbio.com

Exhibition Partner
www.helixbiostructures.com

Exhibition Partner
www.nanotemper.com

Exhibition Partner
www.sigmaaldrich.com

Exhibition Partner
www.tcgls.com

Exhibition Partner
www.pelagobio.com

Exhibition Partner
www.massdynamics.com

Exhibition Partner
www.biognosys.com

Industry Partner
www.orionisbio.com

Industry Partner
www.biotheryx.com

Event Partner
www.biortus.bio

Event Partner
www.deepkinase.com

Event Partner
www.beacon-intelligence.com

Event Partner
www.hybrigenics-services.com

Event Partner
www.aurigeneservices.com

REGISTER NOW

Take the Spotlight: Partner with Us

The Single-Most Important Global Platform to Foster New & Existing Relationships within the Rapidly Expanding TPD & Induced Proximity Field

Over 450 pioneering drug developers from fledgling biotechs, trailblazing established biopharma, and large pharma will descend on Boston, from October 28 – 31 2024, to overcome some of the industry's toughest challenges and bottlenecks.

Can you afford to miss this?

Why the TPD & Induced Proximity Space Is So Hot Right Now:

Therapeutic Potential: with the next generation of degraders now coming through, new avenues to diseases are being opened.

Mechanistic Versatility: by completely removing disease causing proteins, degraders offer therapeutic advantage over many inhibitors.

Expanded Target Landscape: degraders make it possible to target traditionally challenging targets like protein-protein interactions.

Innovation & Investment: a huge influx of investment from venture capital and now large pharma pouring in multi-millions $ to accelerate research and clinical trials.

Positive Early Results: so far promising early signs in preclinic and clinic for PROTACs and now Molecular Glues in oncology, and even now in CNS diseases.

WHO YOU CAN EXPECT TO MEET?

SENIORITY OF ATTENDEES*



- CxO: 11%
- Vice President: 12%
- Director: 16%
- Head / Manager / Project Leader: 20%
- Scientist: 32%
- Professor: 5%
- Other: 4%

COMPANY BREAKDOWN*



*Based on the attendee profile of the 6th Annual TPD Summit 2023

BENEFITS OF PARTNERSHIP:

Brand Visibility & Awareness: display your logo on event materials, our website, brochure, and signage, positioning your brand before industry leaders and potential clients.

Thought Leadership: grab the spotlight by presenting your work within one of our focused tracks or participate in a panel discussion to demonstrate your team's expertise and knowhow.

Networking Opportunities: leverage one of the numerous opportunities at the world's single greatest TPD summit to meet key decision-makers, new customers, existing clients, and other key stakeholders to develop your footing in the community.

New Business: gain access to attendee lists and interact in face-to-face conversations with a specialized pool of all the key players in the space.

Gain Market Insight: as the largest, premier forum, this is the place to stay abreast of latest trends, innovations, and strategies if you want to stay ahead of the curve.

Get the Edge on Competition: partnering can give you insight your competitors won't be getting, as well as distinguish you from the crowd.

Jacob Roberts-Kendall
Senior Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Charlotte Hodgson
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

CONTENTS

REGISTER NOW

hansonwade

Ready to Register?

3 Easy Ways To Book

www.proteindegradation.com/take-part/register

Tel: +1 617 455 4188

Email: info@hansonwade.com

Team Discounts*

- 10% discount – 3+ Attendees
- 15% discount – 5+ Attendees
- 20% discount – 7+ Attendees

*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Top Reasons You Cannot Miss the 7th TPD & Induced Proximity Summit

1. **Unparalleled** access to CEO's thought leadership from **Nurix, Foghorn, Arvinas & Kymera** to guide your pipeline direction
2. **Network** with **550+ TPD experts** bound by the same challenges and hurdles across Discovery, Preclinical, and Clinical
3. **Brand New Datasets** from fledgling biotechs showcasing their *in vivo* efficacy data through to leading clinical candidates paving the way toward approval

Drug Developer Pricing**	Standard Rate	On the Door
Industry Days + New Frontiers Day + Next Generation Day	$5,995 **(Save $300)**	$6,295
Industry Days + New Frontiers Day OR Next Generation Day*	$4,597 **(Save $200)**	$4,797
Industry Days Only	$3,199 **(Save $100)**	$3,299

Academic Pricing***	Standard Rate	On the Door
Industry Days + New Frontiers Day + Next Generation Day	$5,195 **(Save $300)**	$5,495
Industry Days + New Frontiers Day OR Next Generation Day*	$3,997 **(Save $200)**	$4,197
Industry Days Only	$2,799 **(Save $100)**	$2,899

Service/Solution Provider Pricing	Standard Rate	On the Door
Industry Days + New Frontiers Day + Next Generation Day	$6,995 **(Save $300)**	$7,295
Industry Days + New Frontiers Day OR Next Generation Day*	$5,397 **(Save $200)**	$5,597
Industry Days Only	$3,799 **(Save $100)**	$3,899

**To qualify for the drug developer rate your company must have a public drug pipeline and not offer fee-based services. Please visit the website forfull pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Venue

The Westin Copley Place, Boston

10 Huntington Ave, Boston, MA 02116, United States

www.marriott.com/en-us/hotels/boswi-the-westin-copley-place-boston/overview

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

CONTENTS

REGISTER NOW